CStone Pharmaceuticals
HKEX:2616
CStone Pharmaceuticals
HKEX:2616
Price:
7.11
HKD
-0.14%
Market Closed
Market Cap:
HK$10.5B
Relative Value
The Relative Value of one
CStone Pharmaceuticals
stock under the Base Case scenario is
2.03
HKD.
Compared to the current market price of 7.11 HKD,
CStone Pharmaceuticals
is
Overvalued by 71%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Relative Value
Base Case
2.03
HKD
Overvaluation 71%
Multiples Across Competitors
Competitors Multiples
CStone Pharmaceuticals Competitors
CStone Pharmaceuticals Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
|
CStone Pharmaceuticals
HKEX:2616
|
9.7B HKD | 42.2 | -22.6 | -22.7 | -22.7 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
369.9B USD | 6 | 88 | 14.6 | 20.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
190B USD | 5.2 | 24.6 | 14.2 | 14.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
175.3B USD | 5.9 | 20.5 | 12.8 | 15.8 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.3B USD | 9.6 | 29.2 | 22 | 23 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.1B USD | 5.5 | 17.5 | 13 | 14.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67.1B AUD | 3.1 | 34.1 | 11.3 | 14.2 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
36.5B EUR | 10.4 | 33.4 | 36.1 | 36.9 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
